FDA Investigator Daniel W Cline
Daniel W Cline has inspections in 5 countries as of 14 Sep 2023. Daniel W Cline has collaborated with a combinined 2482 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
16
Last Inspection Date:
14 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
Italy,
Hungary,
Croatia
Co-Investigator(s):
Alexander M Kay,
Alexandra B Pitkin,
Amalia C Himaya,
Amalia Himaya,
Amir Alavi,
Anderson,
Angela Shepas,
Anita Narula, PhD,
Arsen Karapetyan,
Azza Talaat,
Barbara J Rincon,
Barbara Jwilimczyk Macri,
Barry Cherney, PhD,
Bichsa T Nguyen,
Bichsa T Tran,
Binh T Nguyen,
Bo Chi, PhD,
Brien C Fox,
Bryan A Galvez,
Carla J Lundi,
Carrie A Hughes,
Caryn M Everly,
Caryn M Mcnab,
Charisse K Green,
Charles D Boison,
Cheron M Portee,
Christina V Santos,
Creighton T Tuzon,
Davinna Ligons, PhD,
Deborah A Greco,
Devaughn Edwards,
Diane Cvan Leeuwen,
Doan T Nguyen, PharmD,
Donna Ltartaglino Besone,
Dr. Mark J Seaton, PhD,
Frances Namuswe, PhD,
Gene D Arcy,
Haley H Seymour,
Haley Seymour,
Haroon Vohra (NMI),
Hasan A Irier, PhD,
Himanshu Gupta, PhD,
Iris C Macinnes,
James C Maclaughlin,
James P Stumpff,
James R Fleckenstein,
Jee Chung, PhD,
Jeffrey P Raimondi,
Jennifer Gogley,
Jennifer M Gogley,
Jerome C Davis,
Jocelyn E Massey,
Jocelyn E Sparks,
Joel Welch, PhD,
Joey V Quitania,
John L Stevens,
John R Myung,
Jose Alopez Rubet,
Juanita Banuelos,
Jun Park, PhD,
Ka L Wong,
Karen J Bak,
Katherine E Jacobitz,
Kathleen B Swat,
Kathleen R Jones, PhD,
Kelvin Cheung,
Kelvin X Sanders,
Kendra A Biddick,
Kim Lthomas Cruse,
Kine Thomas Cruse,
Kristy A Zielny,
Laura Fontan, MS,
Laurissa S Flowers,
Leonard H Lavi,
Liatte Kreuger, PharmD,
Linda F Murphy,
Linda Thai,
Luis A Dasta,
Marcia Britt Williams,
Marcus F Yambot,
Mariza M Jafary,
Mary Ewilkerson Brinsko,
Matthew B Casale,
Maxyne T Lam,
Michelle A Marsh,
Michelle J Hines,
Miguel A Martinez,
Mihaly S Ligmond,
Minh D Phan,
Mohsen Rajabi Abhari, FDA,
Mra Greenc,
Mra Mcculloughj,
Nancy E Byerly,
Nicholas L Hunt,
Nicholas Obiri, PhD,
Nicola M Fenty Stewart,
Omotunde O Osunsanmi,
Paquita F Segarra,
Parul M Patel,
Patrick C Klotzbuecher,
Peter S Diak,
Raymond W Brullo,
Rebecca Rodriguez,
Richmond K Yip,
Robert D Tollefsen,
Robert Darius,
Robert S Sweeton,
Roger F Zabinski,
Ronald L Koller,
Ronda Lebland,
Sarah Arden,
Scott R Nichols, PhD,
Selene T Torres,
Sidney B Priesmeyer,
Sonia R Peterson,
Stanley Au,
Stephanie Mangigian, MS/OSH, RN,
Steven Fong, MS, PhD,
Taichun Qin, PhD,
Tania Y Hall,
Terri L Dodds,
Thao T Kwan,
Thao Tran,
Thao X Tran,
Theresa Kirkham (NMI),
Thomas J Arista,
Timothy P Lafave,
Tonia L Sawyer,
Truong Xuan Nguyen (Andy),
Uttaniti Limchumroon (Tom),
Vashti E Bocker,
Vickie L Anderson,
Vien Q Le,
Vilmary Negron Rodriguez,
Viviana Matta,
William J Leonard,
William S Vitale,
Yumi J Hiramine,
Yvonne C Wilkes
Daniel W Cline's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| February, 2000 | FDA 483 | Pacific Coast Tissue Bank - Form 483, 2000-02-02 |
| August, 2002 | EIR | Pliva Hrvatska d.o.o. - EIR, 2002-09-13 |
| August, 2002 | FDA 483 Response | Pliva Hrvatska d.o.o. - Form 483R, 2002-08-30 |
| August, 2002 | FDA 483 | Xellia Pharmaceuticals Ltd. - Form 483, 2002-08-24 |
| August, 2002 | FDA 483 Response | Xellia Pharmaceuticals Ltd. - Form 483R, 2002-09-13 |
| June, 2000 | EIR | California Transplant Services Inc - EIR, 2000-06-23 |
| January, 2001 | EIR | Curia Italy S.r.l. - EIR, 2001-02-28 |
| November, 2002 | EIR | Allergan Sales, LLC - EIR, 2013-07-26 |
| March, 2000 | EIR | IsoTis OrthoBiologics, Inc. - EIR, 2000-03-20 |
| August, 2002 | FDA 483 | Pliva Hrvatska d.o.o. - Form 483, 2002-08-30 |
| June, 2000 | FDA 483 | CALIFORNIA TRANSPLANT SERVICES, INC. - Form 483, 2000-06-23 |
| October, 2001 | EIR | Amgen, Inc - EIR, 2001-10-26 |
| February, 2000 | FDA 483 Response | Pacific Coast Tissue Bank - Form 483R, 2000-02-20 |
| August, 2002 | EIR | Xellia Pharmaceuticals Ltd. - EIR, 2002-09-13 |
Experience Redica System's NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more